TITLE

Metaplastic Breast Cancer: Clinical Features and Outcomes

AUTHOR(S)
Gibson, Glen R.; Qian, Dajun; Ku, Joseph K.; Lai, Lily L.
PUB. DATE
September 2005
SOURCE
American Surgeon;Sep2005, Vol. 71 Issue 9, p725
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Melaplastic carcinoma of the breast, a neoplasm with both epithelial and mesenchymal elements, represents less than 1 per cent of all breast cancer. We reviewed the records of all patients diagnosed with localized metaplastic breast cancer from 1991 to 2003 al our institution. We identified 21 patients. Mean primary tumor size was 4.62 cm. Eight patients (38% ) had axillary node involvement at presentation. All the tumors were high grade. Only two (10%) of the tumors were hormone receptor positive. Seventeen (81%) of the patients received adjuvant chemotherapy, and 12 (57%) of the patients received radiation. Ten (29%) patients suffered a local recurrence. With a mean follow-up of 46 months, the 5-year disease-free and overall survival was 42 per cent (95% CI: 20% to 65%) and 71 per cent (95% CI: 46% to 96%), respectively. Stage-specific overall survival was 100 per cent, 83 per cent, and 53 per cent for stages I, II, and III, respectively. By multivariate analysis, there was no impact on recurrence or survival with regard to size, age, menopausal status, nodal status, histologic subtype, adjuvant therapy, or extent of surgery. Metaplastic breast cancer is a unique neoplasm that tends to present at an advanced stage and has a propensity for local recurrence. When stratified by stage, however, survival appears similar to that of adenocarcinoma of the breast, and these tumors should be treated as such.
ACCESSION #
18384734

 

Related Articles

  • OK to skip some treatments. Investor's Business Daily // Investors Business Daily;12/16/2013, pA02 

    Some standard cancer treatments, which include chemo, radiation and surgery, can be skipped by breast-cancer patients without a big impact on survival odds, researchers said at an int'l conference. They studied ways to cut back on overtreatment, which can be unnecessary or cause other side...

  • Health system costs for stage-specific breast cancer: a population-based approach. Mittmann, N.; Porter, J. M.; Rangrej, J.; Seung, S. J.; Liu, N.; Saskin, R.; Cheung, M. C.; Leighl, N. B.; Hoch, J. S.; Trudeau, M.; Evans, W. K.; Dainty, K. N.; DeAngelis, C.; Earle, C. C. // Current Oncology;Dec2014, Vol. 21 Issue 6, p281 

    Objective The objective of the present analysis was to determine the publicly funded health care costs associated with the care of breast cancer (BCA) patients by disease stage. Methods Incident cases of female invasive BCA (2005-2009) were extracted from the Ontario Cancer Registry and linked...

  • Effect of Three Decades of Screening Mammography on Breast-Cancer Incidence. Bleyer, Archie; Welch, H. Gilbert // New England Journal of Medicine;11/22/2012, Vol. 367 Issue 21, p1998 

    Background: To reduce mortality, screening must detect life-threatening disease at an earlier, more curable stage. Effective cancer-screening programs therefore both increase the incidence of cancer detected at an early stage and decrease the incidence of cancer presenting at a late stage....

  • A Grounded Explanation of Why Women Present with Advanced Breast Cancer. Taib, Nur; Yip, Cheng; Low, Wah // World Journal of Surgery;Jul2014, Vol. 38 Issue 7, p1676 

    Background: Advanced breast cancer presentation remains a large obstacle in lowering mortality rates in low- and middle-resource countries. This study aims to explore the reasons why women present with breast cancer at an advanced stage. Methods: Purposive sampling of 19 breast cancer patients...

  • Demographic and clinico-pathological characteristics of breast cancer patients with history of oral alendronate use. Şendur, Mehmet; Aksoy, Sercan; Yaman, Şebnem; Arık, Zafer; Özdemir, Nuriye; Zengin, Nurullah; Altundağ, Kadri // Medical Oncology;Dec2012, Vol. 29 Issue 4, p2601 

    Bisphosphonates are the most commonly used agents in the treatment of osteoporosis, and bisphosphonate therapy reduces the risk of skeletally related complications in patients with bone metastases due to malignancy. However, the effect of oral alendronate treatment on clinical and pathological...

  • Vital Signs: Racial Disparities in Breast Cancer Severity -- United States, 2005-2009. Cronin, Kathleen A.; Richardson, Lisa C.; Henley, S. Jane; Miller, Jacqueline W.; Thomas, Cheryll C.; White, Arica; Plescia, Marcus // MMWR: Morbidity & Mortality Weekly Report;11/16/2012, Vol. 61 Issue 45, p922 

    Background: Breast cancer death rates have been declining among U.S. women since 1990 because of early detection and advances in treatment; however, all racial groups have not benefited equally. Methods: Breast cancer incidence, stage at diagnosis, and mortality rates for 2005-2009 for women in...

  • Demographic and clinico-pathological characteristics in patients with triple-negative and non-triple-negative breast cancer. Bulut, Nilufer; Aksoy, Sercan; Dizdar, Omer; Dede, Didem; Arslan, Cagatay; Dogan, Erkan; Gullu, Ibrahim; Ozisik, Yavuz; Altundag, Kadri // Medical Oncology;Dec2011, Vol. 28, p75 

    We investigate retrospectively the demographic and clinico-pathological characteristics of patients with triple-negative breast cancer (TNBC) compared to those with non-TNBC. Patients with breast cancer diagnosed from 1981 to 2008 in our clinic were retrospectively analyzed. Patient demographics...

  • COMMUNICATING ABOUT CANCER RISK IN HIGH-RISK FAMILIES: A COMPARISON BETWEEN BREAST AND OVARIAN CANCER SURVIVORS AND THEIR FEMALE RELATIVES. Mellon, Suzanne; Berry-Bobovski, Lisa; Gold, Robin; Janisse, James; Tainsky, Michael // Oncology Nursing Forum;Jan2007, Vol. 34 Issue 1, p227 

    Although families live with a history of cancer that may signify a genetic risk such as BRCA1/2, few studies have examined communication within families about inherited breast/ovarian cancer risk. Understanding family communication patterns is critical to assist survivors and their family...

  • Positive predictive value of Breast Imaging Reporting and Data System (BI-RADS) categories 3, 4 and 5. Medina Prado, Gérson Luís; Martins Guerra, Maria Tereza Paraguassú // Radiologia Brasileira;may/jun2010, Vol. 43 Issue 3, p171 

    OBJECTIVE: The present study was aimed at evaluating BI-RADS® 3, 4 and 5 categories as positive predictive value for malignancy of non-palpable breast lesions, correlating mammographic and histopathological findings. MATERIALS AND METHODS: In the period from July/2005 to March/2008, 371...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics